Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $36.70.

A number of analysts recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $36.00 price target on shares of Viridian Therapeutics in a report on Tuesday. JMP Securities decreased their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Royal Bank of Canada decreased their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds have recently modified their holdings of the company. Amalgamated Bank raised its position in shares of Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after purchasing an additional 840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock valued at $669,000 after purchasing an additional 876 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Viridian Therapeutics by 2.9% in the first quarter. SG Americas Securities LLC now owns 31,972 shares of the company's stock worth $431,000 after buying an additional 887 shares in the last quarter. Voya Investment Management LLC boosted its position in Viridian Therapeutics by 5.1% during the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after acquiring an additional 1,038 shares during the last quarter. Finally, Tudor Investment Corp ET AL raised its holdings in Viridian Therapeutics by 3.0% in the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock valued at $735,000 after acquiring an additional 1,106 shares during the last quarter.

Viridian Therapeutics Trading Down 1.1%

Shares of NASDAQ:VRDN traded down $0.15 on Friday, hitting $13.53. 140,503 shares of the company's stock were exchanged, compared to its average volume of 1,189,881. The business's 50 day simple moving average is $13.20 and its two-hundred day simple moving average is $16.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.14 and a beta of 0.57. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Viridian Therapeutics's revenue for the quarter was up .0% on a year-over-year basis. Analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.